Mikhael, J., Belhadj-Merzoug, K., Hulin, C., Vincent, L., Moreau, P., Gasparetto, C., … Leleu, X. (2021). A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J, 11(5), 89. https://doi.org/10.1038/s41408-021-00478-4

Mikhael, Joseph, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, et al. “A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.” Blood Cancer J 11, no. 5 (May 12, 2021): 89. https://doi.org/10.1038/s41408-021-00478-4.

Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021 May 12;11(5):89.

Mikhael, Joseph, et al. “A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.” Blood Cancer J, vol. 11, no. 5, May 2021, p. 89. Pubmed, doi:10.1038/s41408-021-00478-4.

Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. Blood Cancer J. 2021 May 12;11(5):89.